INmune Bio Inc.INmune Bio Inc.INmune Bio Inc.

INmune Bio Inc.

No trades
See on Supercharts

INMB fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
INMB has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company